Trial Profile
A retrospective study comparing risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Therapeutic Use
- 11 May 2018 New trial record